As mentioned before, in DESTINY-Breast 04, ILD occurred in 12.1% (45) of patients with HER2-low disease treated with T-DXd, including five grade 3 events, and three treatment-related deaths; the median number of prior therapies in this study was 3 (Range 1–9) [12]. Here, ERBB2 is linked to interstitial lung disease.